The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma

2025-11-28 – Press Releases – www.prnewswire.com

CHENGDU, China, Nov. 28, 2025 /PRNewswire/ — Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”, HKEX: 6990)’s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has…

Read the full article here.